Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Puma Biotechnology
(NQ:
PBYI
)
2.540
+0.100 (+4.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Puma Biotechnology
< Previous
1
2
3
4
Next >
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results
July 20, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
June 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports First Quarter Financial Results
May 04, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
April 20, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
March 14, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 02, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Conference
February 28, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation
February 01, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 11, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Releases Updated Corporate Presentation
January 09, 2023
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
December 07, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
October 27, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 20, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
September 20, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
September 11, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.